Oct 21, 2023, 14:04
Tom Powles: Renal cancer highlights ESMO23
Tom Powles Director of Barts Cancer Centre, shared a post on LinkedIn, saying:
“Renal cancer highlights ESMO23: R3 for Belzuifan vs everolimus: 25% in PFS in pretreated M1. RR look good but OS not there yet. RR also look for belzutifan/cabo (70% 1st line). A new 1st line combo: axi + toliparimab (PD-1) which look like axi/pembro PFS/OS ~0.65 RRs~60%”
Source: Tom Powles/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 2, 2024, 20:23
Dec 2, 2024, 19:24
Dec 2, 2024, 19:20
Dec 2, 2024, 19:16
Dec 2, 2024, 19:06
Dec 2, 2024, 19:02